Xiaodi Yan

Xiaodi Yan

Auto-generated profile, based on publicly available information

Xiaodi Yan

The Affiliated Lianyungang Hospital of xuzhou medical university

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
XYXiaodi Yan
Xiaodi Yan
BWBaoyan Wang
Baoyan Wang
PXPeng Xia
Peng Xia
CLChen Lan
Chen Lan
QWQian Wang
Qian Wang
CJChenxiao Jiang
Chenxiao Jiang
The efficacy and safety of anticoagulant therapy in patients with acute ischemic stroke (AIS) and atrial fibrillation (AF) remain uncertain. This study enrolled 431 AIS and AF patients from Nanjing Drum Tower Hospital between January 2019 and December 2021 and followed for 365 days to determine the associations between anticoagulants and clinical outcomes by assessing modified Rankin Scale (mRS) score, recurrent ischemic stroke/systemic embolism (IS/SE), all-cause mortality, intracranial hemorrhage (ICH) and major bleeding. Final analysis included 400 eligible patients and divided them into antiplatelet group (n = 191) and anticoagulant group (n = 209). Anticoagulant therapy was associated with excellent (mRS 0–1; adjusted odds ratio (aOR), 2.63; 95% confidence interval (CI), 1.61–4.30) and favorable functional outcomes (mRS 0–2; aOR, 2.82; 95% CI, 1.69–4.70) and lower risk of all-cause mortality (adjusted hazard ratio (aHR), 0.35; 95% CI, 0.21–0.57), ICH (aHR, 0.45; 95% CI, 0.23–0.87) and major bleeding (aHR, 0.51; 95% CI, 0.28–0.94), without increasing the risk of recurrent IS/SE (aHR, 0.75; 95% CI, 0.45–1.24). In conclusion, anticoagulant therapy may be a more effective and safer option than antiplatelet therapy for AIS patients with AF.

1 January 2024 in Risk Management and Healthcare Policy
Verified
Journal Article
Open access
PDF file
XYXiaodi Yan
Xiaodi Yan
PXPeng Xia
Peng Xia
HTHanwen Tong
Hanwen Tong
CLChen Lan
Chen Lan
QWQian Wang
Qian Wang
CJChenxiao Jiang
Chenxiao Jiang
Background: Acute ischemic stroke (AIS) in patients with atrial fibrillation (AF) carries a substantial risk of mortality, emphasizing the need for effective risk assessment and timely interventions. This study aimed to develop and validate a practical dynamic nomogram for predicting 3-month mortality in AIS patients with AF. Methods: AIS patients with AF were enrolled and randomly divided into training and validation cohorts. The nomogram was developed based on independent risk factors identified by multivariate logistic regression analysis. The prediction performance of the nomogram was evaluated using the area under the receiver operating characteristic curve (AUC-ROC), calibration plots, decision curve analysis (DCA), and Kaplan-Meier survival analysis. Results: A total of 412 patients with AIS and AF entered final analysis, 288 patients in the training cohort and 124 patients in the validation cohort. The nomogram was developed using age, baseline National Institutes of Health Stroke Scale score, early introduction of novel oral anticoagulants, and pneumonia as independent risk factors. The nomogram exhibited good discrimination both in the training cohort (AUC, 0.851; 95% CI, 0.802– 0.899) and the validation cohort (AUC, 0.811; 95% CI, 0.706– 0.916). The calibration plots, DCA and Kaplan-Meier survival analysis demonstrated that the nomogram was well calibrated and clinically useful, effectively distinguishing the 3-month survival status of patients with AIS and AF, respectively. The dynamic nomogram can be obtained at the website: https://yanxiaodi.shinyapps.io/3-monthmortality/. Conclusion: The dynamic nomogram represents the first predictive model for 3-month mortality and may contribute to managing the mortality risk of patients with AIS and AF.

1 October 2010 in Journal of Medical Colleges of PLA
Verified
Journal Article
Closed access
YXYan Xiaodi
Yan Xiaodi
ZSZhou Shuangqiong
Zhou Shuangqiong
CQChen Qianbo
Chen Qianbo
CCChen Chengwen
Chen Chengwen
YHYuan Hongbin
Yuan Hongbin

1 January 2026 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
JHJia Hu
Jia Hu
PXPeng Xia
Peng Xia
JZJialin Zhang
Jialin Zhang
XYXiaodi Yan
Xiaodi Yan
WGWeihong Ge
Weihong Ge
CJChenxiao Jiang
Chenxiao Jiang
Background: The optimal timing of anticoagulation initiation after acute ischemic stroke (AIS) in patients with non-valvular atrial fibrillation (NVAF) remains uncertain. We evaluated the association between early versus delayed rivaroxaban initiation and clinical outcomes in this population. Methods: In this retrospective, single-center cohort study, 401 hospitalized AIS patients with NVAF receiving rivaroxaban between January 2019 and June 2024 were classified into early (≤7 days) or delayed (>7 days) initiation groups. Primary outcomes were excellent [modified Rankin Scale (mRS) 0-1] and good (mRS 0-2) functional outcomes at 90 days and 12 months. Secondary outcomes included recurrent ischemic stroke, clinically relevant major bleeding, all-cause mortality, composite outcomes, and in-hospital length of stay (LOS). Inverse probability of treatment weighting (IPTW) was applied, followed by regression analyses. Sensitivity and subgroup analyses were performed. Results: After IPTW adjustment, early rivaroxaban initiation was associated with a higher likelihood of achieving mRS 0-1 at 90 days (aOR 1.76, 95% CI 1.02-3.05) and 12 months (aOR 1.82, 95% CI 1.08-3.06), as well as a shorter LOS. No significant differences were observed for mRS 0-2 or other secondary outcomes. Sensitivity analyses yielded consistent results, and subgroup analyses suggested a trend toward greater benefit among patients with higher baseline stroke severity (NIHSS >7). Conclusion: Early rivaroxaban initiation after AIS in patients with NVAF was associated with improved excellent functional outcomes without an apparent increase in adverse events, supporting its potential feasibility in routine practice and warrant confirmation in larger prospective studies.